In 2025, it was estimated that there would be over 972 thousand new cancer cases among women in the United States. This statistic illustrates the estimated number of new cancer cases and deaths in the United States for 2025, by gender.

Cancer was responsible for around 142 deaths per 100,000 population in the United States in 2022. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated 65,790 deaths among men alone in 2024. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as 99 percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around 81 percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. A recent poll indicated that many U.S. adults believed smoking cigarettes and using other tobacco products increased a person’s risk of developing cancer, but a much smaller percentage believed the same for proven risk factors such as obesity and drinking alcohol.

BackgroundThe exponential growth of the cancer burden attributable to metabolic factors deserves global attention. We investigated the trends of cancer mortality attributable to metabolic factors in 204 countries and regions between 1990 and 2019.MethodsWe extracted data from the Global Burden of Disease Study (GBD) 2019 and assessed the mortality, age-standardized death rate (ASDR), and population attributable fractions (PAFs) of cancers attributable to metabolic factors. Average annual percentage changes (AAPCs) were calculated to assess the changes in the ASDR. The cancer mortality burden was evaluated according to geographic location, SDI quintiles, age, sex, and changes over time.ResultsCancer attributable to metabolic factors contributed 865,440 (95% UI, 447,970-140,590) deaths in 2019, a 167.45% increase over 1990. In the past 30 years, the increase in the number of deaths and ASDR in lower SDI regions have been significantly higher than in higher SDI regions (from high to low SDIs: the changes in death numbers were 108.72%, 135.7%, 288.26%, 375.34%, and 288.26%, and the AAPCs were 0.42%, 0.58%, 1.51%, 2.36%, and 1.96%). Equatorial Guinea (AAPC= 5.71%), Cabo Verde (AAPC=4.54%), and Lesotho (AAPC=4.42%) had the largest increase in ASDR. Large differences were observed in the ASDRs by sex across different SDIs, and the male-to-female ratios of ASDR were 1.42, 1.50, 1.32, 0.93, and 0.86 in 2019. The core population of death in higher SDI regions is the age group of 70 years and above, and the lower SDI regions are concentrated in the age group of 50-69 years. The proportion of premature deaths in lower SDI regions is significantly higher than that in higher SDI regions (from high to low SDIs: 2%, 4%, 7%, 7%, and 9%). Gastrointestinal cancers were the core burden, accounting for 50.11% of cancer deaths attributable to metabolic factors, among which the top three cancers were tracheal, bronchus, and lung cancer, followed by colon and rectum cancer and breast cancer.ConclusionsThe cancer mortality burden attributable to metabolic factors is shifting from higher SDI regions to lower SDI regions. Sex differences show regional heterogeneity, with men having a significantly higher burden than women in higher SDI regions but the opposite is observed in lower SDI regions. Lower SDI regions have a heavier premature death burden. Gastrointestinal cancers are the core of the burden of cancer attributable to metabolic factors.

Azerbaijan Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 27.200 % in 2019. This records a decrease from the previous number of 27.400 % for 2018. Azerbaijan Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 30.050 % from Dec 2000 (Median) to 2019, with 20 observations. The data reached an all-time high of 32.500 % in 2000 and a record low of 27.200 % in 2019. Azerbaijan Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Azerbaijan – Table AZ.World Bank.WDI: Social: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).;World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).;Weighted average;This is the Sustainable Development Goal indicator 3.4.1 [https://unstats.un.org/sdgs/metadata/].

Note: DPH is updating and streamlining the COVID-19 cases, deaths, and testing data. As of 6/27/2022, the data will be published in four tables instead of twelve. The COVID-19 Cases, Deaths, and Tests by Day dataset contains cases and test data by date of sample submission. The death data are by date of death. This dataset is updated daily and contains information back to the beginning of the pandemic. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-Cases-Deaths-and-Tests-by-Day/g9vi-2ahj. The COVID-19 State Metrics dataset contains over 93 columns of data. This dataset is updated daily and currently contains information starting June 21, 2022 to the present. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-State-Level-Data/qmgw-5kp6 . The COVID-19 County Metrics dataset contains 25 columns of data. This dataset is updated daily and currently contains information starting June 16, 2022 to the present. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-County-Level-Data/ujiq-dy22 . The COVID-19 Town Metrics dataset contains 16 columns of data. This dataset is updated daily and currently contains information starting June 16, 2022 to the present. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-Town-Level-Data/icxw-cada . To protect confidentiality, if a town has fewer than 5 cases or positive NAAT tests over the past 7 days, those data will be suppressed. COVID-19 cases and associated deaths that have been reported among Connecticut residents, broken down by race and ethnicity. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. Deaths reported to the either the Office of the Chief Medical Examiner (OCME) or Department of Public Health (DPH) are included in the COVID-19 update. The following data show the number of COVID-19 cases and associated deaths per 100,000 population by race and ethnicity. Crude rates represent the total cases or deaths per 100,000 people. Age-adjusted rates consider the age of the person at diagnosis or death when estimating the rate and use a standardized population to provide a fair comparison between population groups with different age distributions. Age-adjustment is important in Connecticut as the median age of among the non-Hispanic white population is 47 years, whereas it is 34 years among non-Hispanic blacks, and 29 years among Hispanics. Because most non-Hispanic white residents who died were over 75 years of age, the age-adjusted rates are lower than the unadjusted rates. In contrast, Hispanic residents who died tend to be younger than 75 years of age which results in higher age-adjusted rates. The population data used to calculate rates is based on the CT DPH population statistics for 2019, which is available online here: https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Population/Population-Statistics. Prior to 5/10/2021, the population estimates from 2018 were used. Rates are standardized to the 2000 US Millions Standard population (data available here: https://seer.cancer.gov/stdpopulations/). Standardization was done using 19 age groups (0, 1-4, 5-9, 10-14, ..., 80-84, 85 years and older). More information about direct standardization for age adjustment is available here: https://www.cdc.gov/nchs/data/statnt/statnt06rv.pdf Categories are mutually exclusive. The category “multiracial” includes people who answered ‘yes’ to more than one race category. Counts may not add up to total case counts as data on race and ethnicity may be missing. Age adjusted rates calculated only for groups with more than 20 deaths. Abbreviation: NH=Non-Hispanic. Data on Connecticut deaths were obtained from the Connecticut Deaths Registry maintained by the DPH Office of Vital Records. Cause of death was determined by a death certifier (e.g., physician, APRN, medical

BackgroundTo estimate the global burden of pancreatic cancer in 2019 and 2021 including incidence, mortality, and disability-adjusted-life-years (DALYs).MethodsData on pancreatic cancer incidence, mortality and DALYs were downloaded from the Global Health Data Exchange. The 95% uncertainty intervals (UIs) were reported for annual numbers and rates (per 100,000 populations).ResultsIn 2021, there were 508,532 (95% UI: 462,09 to 547,208) incident cases of pancreatic cancer globally, of which 273,617 (250,808 to 299,347; 53.8%) were in males. The age-standardized incidence rate was 6.0 (5.5 to 6.5) per 100,000 people in 2019 and decreased to 5.9 (5.4 to 6.4) per 100,000 people in 2021. There was a 3.9% increase in the number of deaths from pancreatic cancer from 486,869 (446,272 to 517,185) in 2019 to 505,752 (461,224 to 543,899) in 2021. There was a 3.5% increase in DALYs due to pancreatic cancer, increasing from 10.9 million (10.1 to 11.7) in 2019 to 11.3 million (10.5 to 12.2) in 2021. In 2021, the highest age-standardized death rates were observed in Greenland and Monaco, and the highest age-standardized DALY rates were observed in Greenland and Uruguay. The numbers of incident cases and deaths peaked at the ages of 70 to 74 years. The pancreatic cancer burden increased as the socio-demographic index increased. To 2044, the number of incident cases and deaths will be more than 875 thousand and 879 thousand, respectively.ConclusionThe disease burden of pancreatic cancer remains high, especially in high-income regions. More cancer prevention measures are needed in the future to reduce the burden of pancreatic cancer.

In 2022, there were 18.7 deaths from prostate cancer per 100,000 men in the United States. This statistic shows the prostate cancer death rate in the United States from 1975 to 2022.

This publication reports on newly diagnosed cancers registered in England during 2022. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document. Cancer registration estimates are provided for: • Incidence of cancer using groupings that incorporate both the location and type of cancer by combinations of gender, age, deprivation, and stage at diagnosis (where appropriate) for England, former Government office regions, Cancer alliances and Integrated care boards • Incidence and mortality (using ICD-10 3-digit codes) by gender and age group for England, former Government office regions, Cancer alliances and Integrated care boards This publication will report on 2022 cancer registrations only, trends will not be reported as the required re-stated populations for 2012 to 2020 are not expected to be published by the Office of National Statistics (ONS) until Winter 2024.

In 2021, there were 8,224 deaths in the United States due to melanoma of the skin. The highest number of deaths within the given period due to melanoma was reported in 2013, with 9,394 deaths. This statistic describes the number of deaths due to melanoma of the skin in the United States from 1999 to 2021.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

Central African Republic CF: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 36.000 % in 2019. This records a decrease from the previous number of 36.500 % for 2018. Central African Republic CF: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 39.250 % from Dec 2000 (Median) to 2019, with 20 observations. The data reached an all-time high of 41.700 % in 2000 and a record low of 36.000 % in 2019. Central African Republic CF: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Central African Republic – Table CF.World Bank.WDI: Social: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).;World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).;Weighted average;This is the Sustainable Development Goal indicator 3.4.1 [https://unstats.un.org/sdgs/metadata/].

Find data on deaths of Massachusetts residents. Information is obtained from death certificates received by the Registry of Vital Records and Statistics.

Canada CA: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 9.600 % in 2019. This records a decrease from the previous number of 9.800 % for 2018. Canada CA: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 11.300 % from Dec 2000 (Median) to 2019, with 20 observations. The data reached an all-time high of 14.400 % in 2000 and a record low of 9.600 % in 2019. Canada CA: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Canada – Table CA.World Bank.WDI: Social: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).;World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).;Weighted average;This is the Sustainable Development Goal indicator 3.4.1 [https://unstats.un.org/sdgs/metadata/].

Chad TD: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 22.700 % in 2019. This records a decrease from the previous number of 23.200 % for 2018. Chad TD: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 24.550 % from Dec 2000 (Median) to 2019, with 20 observations. The data reached an all-time high of 24.900 % in 2003 and a record low of 22.700 % in 2019. Chad TD: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Chad – Table TD.World Bank.WDI: Social: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).;World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).;Weighted average;This is the Sustainable Development Goal indicator 3.4.1 [https://unstats.un.org/sdgs/metadata/].

This table contains 33048 series, with data for years 2000/2002 - 2010/2012 (not all combinations necessarily have data for all years), and was last released on 2016-03-16. This table contains data described by the following dimensions (Not all combinations are available): Geography (36 items: Total, census metropolitan areas; St. John's, Newfoundland and Labrador; Halifax, Nova Scotia;Moncton, New Brunswick; ...), Sex (3 items: Both sexes; Males; Females), Indicators (2 items: Mortality; Potential years of life lost), Selected causes of death (ICD-10) (17 items: Total, all causes of death; All malignant neoplasms (cancers); Colorectal cancer; Lung cancer; ...), Characteristics (9 items: Number; Low 95% confidence interval, number; High 95% confidence interval, number; Rate; ...).

Directly age standardised mortality rate from breast cancer for females in the respective time period per 100,000 registered female patients. March 2020: In addition to the changes in March 2019, the indicator production process has been fully automated. As a result there are two changes to this publication: 1) Data in this file are published for 2016-2018 only; all data is based on the most recent methodology. For the historic time series of this indicator please refer to the zip files in the June 2018 publication: https://digital.nhs.uk/data-and-information/publications/clinical-indicators/ccg-outcomes-indicator-set/archive/ccg-outcomes-indicator-set---june-2018 Please note, neither version of the file contains data for 2015-2017; changes in the data processing meant the 2015 data was not comparable to the 2016 and 2017 data processed under the new method. 2) Data are run against CCGs which were in existence at the time of processing. As of the March 2019 release the processing of the Primary Care Mortality Database (PCMD) and the standard population used to calculate the indicator for new data periods changed; this file now contains only those data periods processed under the new method. For the historic time series of this indicator please refer to the June 2018 publication referenced above. Legacy unique identifier: P01819

Directly age standardised mortality rate from breast cancer for females in the respective time period per 100,000 registered female patients. October 2022: This is the last CCGOIS publication. All Clinical Commissioning Groups (CCGs) were statutorily abolished on the 1 July 2022, and from this point all statutory obligations are managed by the Integrated Care Boards (ICBs). ICBs were established as statutory bodies from July 2022 and succeed Sustainability and Transformation Partnerships (STPs). These came into effect on 1 July 2022. A transition phase has been implemented from 1 July 2022, during which the 106 Organisation Data Service (ODS) codes that identified CCGs will be temporarily retained, but the names will be changed to identify the ‘Sub ICB Location’. March 2020: In addition to the changes in March 2019, the indicator production process has been fully automated. As a result there are two changes to this publication: 1) Data in this file are published for 2016-2018 only; all data is based on the most recent methodology. For the historic time series of this indicator please refer to the zip files in the June 2018 publication: https://digital.nhs.uk/data-and-information/publications/clinical-indicators/ccg-outcomes-indicator-set/archive/ccg-outcomes-indicator-set---june-2018 Please note, neither version of the file contains data for 2015-2017; changes in the data processing meant the 2015 data was not comparable to the 2016 and 2017 data processed under the new method. 2) Data are run against CCGs which were in existence at the time of processing. As of the March 2019 release the processing of the Primary Care Mortality Database (PCMD) and the standard population used to calculate the indicator for new data periods changed; this file now contains only those data periods processed under the new method. For the historic time series of this indicator please refer to the June 2018 publication referenced above. Legacy unique identifier: P01819

In 2023, there were approximately 750.5 deaths by all causes per 100,000 inhabitants in the United States. This statistic shows the death rate for all causes in the United States between 1950 and 2023. Causes of death in the U.S. Over the past decades, chronic conditions and non-communicable diseases have come to the forefront of health concerns and have contributed to major causes of death all over the globe. In 2022, the leading cause of death in the U.S. was heart disease, followed by cancer. However, the death rates for both heart disease and cancer have decreased in the U.S. over the past two decades. On the other hand, the number of deaths due to Alzheimer’s disease – which is strongly linked to cardiovascular disease- has increased by almost 141 percent between 2000 and 2021. Risk and lifestyle factors Lifestyle factors play a major role in cardiovascular health and the development of various diseases and conditions. Modifiable lifestyle factors that are known to reduce risk of both cancer and cardiovascular disease among people of all ages include smoking cessation, maintaining a healthy diet, and exercising regularly. An estimated two million new cases of cancer in the U.S. are expected in 2025.

Bulgaria BG: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 24.200 % in 2019. This records a decrease from the previous number of 24.400 % for 2018. Bulgaria BG: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 25.650 % from Dec 2000 (Median) to 2019, with 20 observations. The data reached an all-time high of 28.500 % in 2000 and a record low of 23.800 % in 2013. Bulgaria BG: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Bulgaria – Table BG.World Bank.WDI: Social: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).;World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).;Weighted average;This is the Sustainable Development Goal indicator 3.4.1 [https://unstats.un.org/sdgs/metadata/].

BackgroundThe purpose of this study is to assess the burden of thyroid cancer over the course of 30 years in 204 countries and territories.MethodsData from the Global Burden of Disease (GBD) 2019 database was analyzed to extract information on prevalence, deaths, DALYs(disability-adjusted life-years), YLL(years of life los), YLD(years lived with disability), and their corresponding age-standardized rates at global, regional, and national levels. The primary focus of the study was to examine trends in thyroid cancer from 1990 to 2019, specifically looking at the Estimated Annual Percentage Change (EAPC) for ASPR, ASDR, and ASDR. Additionally, the study investigated the relationship between cancer burden and the Socio-Demographic Index (SDI).ResultsGlobally, there will be approximately 18.3 million thyroid cancer (TC) cases in 2019; China and the USA are projected to be the most significant with 310,327 and 220,711 cases (16.17 and 14.82 cases per 100,000 people, respectively).Over the period from 1990 to 2019, age-standardized prevalence rates exhibited a global rise, whereas deaths and DALYs saw a decrease(EAPC:1.63, –0.15- –0.14, respectively). Significantly, the age-standardized prevalence rate increased in 21 GBD regions, affecting 195 out of 204 countries or territories. Over the studied period, thyroid cancer cases, deaths, and DALYs were consistently higher among females than males. Furthermore, a higher Socio-demographic Index was associated with increased age-standardized prevalence rates.